172 related articles for article (PubMed ID: 38295285)
1. Clinical features of neurotoxicity after CD19 CAR T-cell therapy in mantle cell lymphoma.
Nie EH; Su YJ; Baird JH; Agarwal N; Bharadwaj S; Weng WK; Smith M; Dahiya S; Han MH; Dunn JE; Kipp LB; Miklos DB; Scott BJ; Frank MJ
Blood Adv; 2024 Mar; 8(6):1474-1486. PubMed ID: 38295285
[TBL] [Abstract][Full Text] [Related]
2. CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results.
Park JH; Nath K; Devlin SM; Sauter CS; Palomba ML; Shah G; Dahi P; Lin RJ; Scordo M; Perales MA; Shouval R; Tomas AA; Cathcart E; Mead E; Santomasso B; Holodny A; Brentjens RJ; Riviere I; Sadelain M
Nat Med; 2023 Jul; 29(7):1710-1717. PubMed ID: 37400640
[TBL] [Abstract][Full Text] [Related]
3. Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy.
Gazeau N; Liang EC; Wu QV; Voutsinas JM; Barba P; Iacoboni G; Kwon M; Ortega JLR; López-Corral L; Hernani R; Ortiz-Maldonado V; Martínez-Cibrian N; Martinez AP; Maziarz RT; Williamson S; Nemecek ER; Shadman M; Cowan AJ; Green DJ; Kimble E; Hirayama AV; Maloney DG; Turtle CJ; Gauthier J
Transplant Cell Ther; 2023 Jul; 29(7):430-437. PubMed ID: 37031746
[TBL] [Abstract][Full Text] [Related]
4. Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy.
Smith DA; Kikano E; Tirumani SH; de Lima M; Caimi P; Ramaiya NH
Radiology; 2022 Feb; 302(2):438-445. PubMed ID: 34751616
[TBL] [Abstract][Full Text] [Related]
5. Use of long-term corticosteroids in patients treated with CAR T-cell therapy.
Hashmi H; McGann M; Greenwell BI
J Oncol Pharm Pract; 2023 Mar; 29(2):473-476. PubMed ID: 35635259
[TBL] [Abstract][Full Text] [Related]
6. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S
Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Toxicity of CD19 Chimeric Antigen Receptor T Cell Therapy for Lymphoma in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis.
Yamshon S; Gribbin C; Chen Z; Demetres M; Pasciolla M; Alhomoud M; Martin P; Shore T
Transplant Cell Ther; 2024 Jan; 30(1):73.e1-73.e12. PubMed ID: 37279856
[TBL] [Abstract][Full Text] [Related]
8. Multifocal demyelinating leukoencephalopathy and oligodendroglial lineage cell loss with immune effector cell-associated neurotoxicity syndrome (ICANS) following CD19 CAR T-cell therapy for mantle cell lymphoma.
Nie EH; Ahmadian SS; Bharadwaj SN; Acosta-Alvarez L; Threlkeld ZD; Frank MJ; Miklos DB; Monje M; Scott BJ; Vogel H
J Neuropathol Exp Neurol; 2023 Jan; 82(2):160-168. PubMed ID: 36592076
[TBL] [Abstract][Full Text] [Related]
9. Frontal Intermittent Rhythmic Delta Activity Is a Useful Diagnostic Tool of Neurotoxicity After CAR T-Cell Infusion.
Huby S; Gelisse P; Tudesq JJ; Labauge P; Duflos C; Cartron G; Gallerand MA; Platon L; Badiou S; Lamure S; Menjot de Champfleur N; Ayrignac X; Taieb G
Neurol Neuroimmunol Neuroinflamm; 2023 Jul; 10(4):. PubMed ID: 37059470
[TBL] [Abstract][Full Text] [Related]
10. Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes.
Holtzman NG; Xie H; Bentzen S; Kesari V; Bukhari A; El Chaer F; Lutfi F; Siglin J; Hutnick E; Gahres N; Ruehle K; Ahmad H; Shanholtz C; Kocoglu MH; Badros AZ; Yared JA; Hardy NM; Rapoport AP; Dahiya S
Neuro Oncol; 2021 Jan; 23(1):112-121. PubMed ID: 32750704
[TBL] [Abstract][Full Text] [Related]
11. Continuous EEG monitoring detects nonconvulsive seizure and Ictal-Interictal Continuum abnormalities in moderate to severe ICANS following systemic CAR-T therapy.
Satyanarayan S; Spiegel J; Hovsepian D; Markert M; Thomas R; Muffly L; Miklos D; Graber K; Scott BJ
Neurohospitalist; 2023 Jan; 13(1):53-60. PubMed ID: 36531846
[TBL] [Abstract][Full Text] [Related]
12. Modified EASIX scores predict severe CRS/ICANS in patients with acute myeloid leukemia following CLL1 CAR-T cell therapy.
Zhao Y; Zhang X; Zhang M; Guo R; Zhang Y; Pu Y; Zhu H; Liu P; Zhang Y; He X; Lyu C; Lyu H; Xiao X; Zhao M
Ann Hematol; 2024 Mar; 103(3):969-980. PubMed ID: 38214708
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
Caimi PF; Pacheco Sanchez G; Sharma A; Otegbeye F; Ahmed N; Rojas P; Patel S; Kleinsorge Block S; Schiavone J; Zamborsky K; Boughan K; Hillian A; Reese-Koc J; Maschan M; Dropulic B; Sekaly RP; de Lima M
Front Immunol; 2021; 12():745320. PubMed ID: 34712233
[TBL] [Abstract][Full Text] [Related]
14. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma.
Strati P; Nastoupil LJ; Westin J; Fayad LE; Ahmed S; Fowler NH; Hagemeister FB; Lee HJ; Iyer SP; Nair R; Parmar S; Rodriguez MA; Samaniego F; Steiner RE; Wang M; Pinnix CC; Adkins S; Claussen CM; Martinez CS; Hawkins MC; Johnson NA; Singh P; Mistry HE; Horowitz S; George S; Feng L; Kebriaei P; Shpall EJ; Neelapu SS; Tummala S; Chi TL
Blood Adv; 2020 Aug; 4(16):3943-3951. PubMed ID: 32822484
[TBL] [Abstract][Full Text] [Related]
15. Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS).
Wehrli M; Gallagher K; Chen YB; Leick MB; McAfee SL; El-Jawahri AR; DeFilipp Z; Horick N; O'Donnell P; Spitzer T; Dey B; Cook D; Trailor M; Lindell K; Maus MV; Frigault MJ
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 34996813
[TBL] [Abstract][Full Text] [Related]
16. Thrombotic Events Are Unusual Toxicities of Chimeric Antigen Receptor T-Cell Therapies.
Schorr C; Forindez J; Espinoza-Gutarra M; Mehta R; Grover N; Perna F
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176053
[TBL] [Abstract][Full Text] [Related]
17. Impact of diagnostic investigations in the management of CAR T-cell-associated neurotoxicity.
Mauget M; Lemercier S; Quelven Q; Maamar A; Lhomme F; De Guibert S; Houot R; Manson G
Blood Adv; 2024 May; 8(10):2491-2498. PubMed ID: 38501964
[TBL] [Abstract][Full Text] [Related]
18. Neurological management and work-up of neurotoxicity associated with CAR T cell therapy.
Möhn N; Bonda V; Grote-Levi L; Panagiota V; Fröhlich T; Schultze-Florey C; Wattjes MP; Beutel G; Eder M; David S; Körner S; Höglinger G; Stangel M; Ganser A; Koenecke C; Skripuletz T
Neurol Res Pract; 2022 Jan; 4(1):1. PubMed ID: 35000613
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of CD19 CAR-T cell therapy for patients with B cell acute lymphoblastic leukemia involving extramedullary relapse.
Huang L; Zhang M; Wei G; Zhao H; Hu Y; Huang H
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):151-159. PubMed ID: 36161297
[TBL] [Abstract][Full Text] [Related]
20. Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors.
Miller A; Daum R; Wang T; Wu M; Tat C; Pfeiffer T; Navai S; Heczey A; Hegde M; Ahmed N; Whittle SB; Hill L; Martinez C; Krance R; Ramos CA; Rouce RH; Lulla P; Heslop HE; Omer B; Shekar M
Cytotherapy; 2024 May; ():. PubMed ID: 38819365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
